Surfactant for acute respiratory failure in children: where should it fit in our treatment algorithm?
In a recent meta-analysis, surfactant administration in paediatric acute respiratory failure was associated with improved oxygenation, reduced mortality, increased ventilator-free days and reduced duration of ventilation. Surfactant is expensive, however, and its use involves installation of large volumes into the lungs, resulting in transient hypoxia and hypotension in some patients. Many questions also remain unanswered, such the as optimum dosage and the timing of administration of surfactant. The merits of surfactant administration should therefore still be decided on an individual case-by-case basis.
Margrid
M
Schindler
D002648:Child; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D011663:Pulmonary Surfactants / Q000191:economics / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000628:therapy*; D016896:Treatment Outcome
D011663:Pulmonary Surfactants